

References

S-143

1. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Chronic myeloid leukemia. Version 1.2022.
2. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Acute lymphoblastic leukemia. Version 1.2021.
3. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Pediatric acute lymphoblastic leukemia. Version 1.2022.
4. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Multiple myeloma. Version 1.2022.
5. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Hodgkin lymphoma. Version 4.2021.
6. Mo X, Zhang X, Xu L, et al. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: Prognostic factors and clinical outcomes. *Euro J Haematol*. 2016;96(3):297-308.
7. Vaezi M, Zokaasadi M, Shahsavari Pour S, et al. The role of donor leukocyte infusions in the treatment of relapsed acute leukemia after allogeneic stem cell transplantation: A retrospective analysis. *Int J Hematol-Oncol Stem Cell Res*. 2018;12(3):184-191.
8. Miyamoto T, Fukada T, Nakashima M, et al. Donor leukocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan Marrow Donor Program. *Biol Blood Marrow Transplant*. 2017;23:938-944.
9. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Acute myeloid leukemia. Version 3.2021.
10. Aladag E, Goker H, Buyukasik Y, Demiroglu H. Effect of salvage chemotherapy before donor lymphocyte infusion in patients with relapse after allogeneic hematologic stem cell transplantation. *Transplant Proc*. 2021;53(1):391-395.
11. Ali T, Behfar M, Mohseni R, Salajegheh P, et al. Escalated dose donor lymphocyte infusion treatment in patients with primary immune deficiencies after HSCT with reduced-intensity conditioning regimen. *Hematol Oncol Stem Cell Ther*. 2021:S1658-3876(21)00059-5.